Company: RPTX
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030405
Chunk: 81

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 81
---

     
    $
    84,717

    $
    111,268

    .

    Supplemental Disclosure Of Cash Flow Information:

    Cash interest received
     
    $
    2,380

    $
    3,089

    Cash taxes paid, net
     
    $
    139

    $
    4,945

    Right-of-use assets obtained in exchange for new operating lease liability
     
    $
    957

    $
    149

The accompanying notes are an integral part of these consolidated financial statements 

105

REPARE THERAPEUTICS INC. 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 

(Amounts in U.S. dollars, except per share data, unless otherwise specified) 

1. Organization and Nature of BusinessRepare Therapeutics Inc. (“Repare” or the “Company”) is a precision medicine oncology company focused on the development of synthetic lethality-based therapies to patients with cancer. The Company was incorporated under the Canada Business Corporations Act on September 6, 2016. On June 23, 2020, immediately prior to the completion of its initial public offering (the “IPO”), the Company was continued as a corporation under the Business Corporations Act (Québec).Since inception, the Company has incurred operating losses. As of December 31, 2024, the Company had an accumulated deficit of $417.8 million. The Company does not have any products approved for sale and has financed its operations primarily through equity financings and funding from its collaboration and license agreements. Based on its current operating plan, the Company expects that its existing cash and cash equivalents and marketable securities on hand will be sufficient to fund its operating and capital expenditures for at least one year from the date of the issuance of these consolidated financial statements.There can be no assurance that the Company will be able to obtain additional debt or equity financing, or generate product revenue or revenue from collaboration agreements, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition.

2. Summary of Significant Accounting PoliciesBasis of PresentationThe accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards